...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical lung cancer >Long-Term Survival with Concurrent Chemoradiation Therapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small-Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S9504).
【24h】

Long-Term Survival with Concurrent Chemoradiation Therapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small-Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S9504).

机译：IIIB期非小细胞肺癌合并放化疗联合多西他赛的长期生存：西南肿瘤组II期研究（S9504）。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Here we report 5-year survival data from S9504, a Southwest Oncology Group phase II trial evaluating consolidation docetaxel after concurrent cisplatin/etoposide and thoracic radiation therapy in patients with pathologically documented stage IIIB non-small-cell lung cancer. Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation. Patients and Methods: Treatment consisted of cisplatin 50 mg/m2 per day on days 1, 8, 29, and 36; etoposide 50 mg/m2 per day on days 1-5 and 29-33; and concurrent thoracic radiation therapy (total dose, 61 Gy). Consolidation docetaxel (75 mg/m2 initial dose) started 4-6 weeks after completion of chemotherapy. Results: Concurrent chemotherapy was generally well tolerated, with a low level of radiation-related esophagitis; 2 patients died from pneumonitis. Grade 3/4 neutropenia during consolidation docetaxel was common. At a median follow-up of 71 months, median progression-free survival was 16 months; median survival 26 months; and 3-, 4-, and 5-year survival rates were 40%, 29%, and 29%, respectively. Brain metastasis was the most common site of failure. In the predecessor trial S9019, median survival was 15 months, and 3-, 4-, and 5-year survival rates were 17%, 17%, and 17%, respectively. Conclusion: The 5-year survival rate in S9540 of 29% compares favorably with the predecessor trial S9019 and other treatment approaches currently used in this patient population. A phase III trial designed to validate the concept of consolidation docetaxel is presently under way.
机译：目的：在此我们报告S9504的5年生存数据，这是一项西南肿瘤小组II期临床试验，该试验评估了病理记录的IIIB期非小细胞肺癌患者同时进行顺铂/依托泊苷和胸腔放疗后的巩固多西他赛治疗。将生存结果与既往资格，分期标准和治疗相同的前项研究（S9019）进行比较，但多西紫杉醇合并治疗除外。患者和方法：第1、8、29和36天每天使用顺铂50 mg / m2进行治疗; 1-5和29-33天每天使用依托泊苷50 mg / m2;并同时进行胸腔放疗（总剂量为61 Gy）。化疗完成后4-6周开始合并多西他赛（75 mg / m2初始剂量）。结果：并行化疗一般耐受良好，与放射有关的食管炎水平低; 2例患者死于肺炎。巩固多西他赛期间3/4级中性粒细胞减少是常见的。中位随访71个月，中位无进展生存期为16个月。中位生存期26个月; 3年，4年和5年生存率分别为40％，29％和29％。脑转移是最常见的失败部位。在先前的试验S9019中，中位生存期为15个月，而3年，4年和5年生存率分别为17％，17％和17％。结论：S9540的5年生存率为29％，与之前的S9019试验和目前在该患者人群中使用的其他治疗方法相比具有优势。目前正在进行一项旨在验证巩固多西他赛概念的III期试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号